Interim results saw strong revenue growth, especially from the A&D and Lifesciences divisions, with continued progress in rejuvenating revenue growth and returning the group to higher margins. Continued internal actions coupled with acquisitive activity have helped, while recent acquisitions are proving to add capability and offering synergies and cross-selling opportunities. Despite challenging markets and fast-changing tariff environments, the group appears well placed and management indicates ....
